Trial intelligence / Profile preview

KPS-0373 (Rovatirelin) in Spinocerebellar Degeneration

NCT01004016Phase 2Completed

Sponsor
Kissei Pharmaceutical Co., Ltd.
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of rovatirelin in spinocerebellar degeneration (SCD), sponsored by Kissei Pharmaceutical Co., Ltd.. Status: completed.

02

Drugs

rovatirelin
03

Conditions

spinocerebellar degeneration (SCD)

Beyond the preview

Go deeper on NCT01004016.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01004016.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call